Dr. Howard Verrico reports

SIRONA BIOCHEM PROCEEDS TO FIRST CLINICAL TESTS FOR HIGHER CONCENTRATIONS TO INCREASE COMMERCIAL VALUE OF SKIN LIGHTENING COMPOUND TFC-1067

Testing of the higher concentration formulation of Sirona Biochem Corp.'s TFC-1067, first announced in June, 2019, will proceed to human patch test, followed by a human repeat insult patch test (HRIPT).

Sirona's scientific team at TFChem and the senior toxicologist at CEHTRA have reviewed recent in-vitro safety assays and verified that the compound can be tested at double the prior concentration. This concentration was chosen as the company aims to achieve maximum efficacy while maintaining TFC-1067's excellent safety profile.

The human patch test for cutaneous irritation will be conducted under physician supervision at Cosmepar in France. Cosmepar's specialized services include evaluating the tolerance of cosmetic products. The results from this test are expected within four weeks.

In addition, a human repeat insult patch test (HRIPT) will be conducted to determine any potential irritation or sensitization issues. The HRIPT will be performed on 100 volunteers selected by Dermscan. Results are expected in January, 2020.

The higher concentration is being used in Sirona's next-generation formulation developed specifically to maximize the efficacy of TFC-1067. The formulation was developed by cosmetic expert, Gael Boutry of Global Beauty Consulting in France.

"We are excited to make this progress towards a second clinical trial of TFC-1067. The in-vitro testing has allowed us to safely double the concentration, but the in-vitro tests have their own limitations so anything over double has been deferred at this time. Safety is our priority and we will proceed to develop TFC-1067 in a stepwise approach. The new formulation is also anticipated to make a significant improvement in efficacy of TFC-1067," said Dr. Howard Verrico, chief executive officer of Sirona Biochem.

"A full clinical trial to assess efficacy is anticipated to begin in the first quarter of 2020. A further update will be made prior to this trial. All testing will be done with cash on hand and will not delay any ongoing partnering discussions. TFC-1067 0.2 per cent has already proven superior to hydroquinone 2 per cent in creating a uniform skin tone and we anticipate even more exciting results with the new higher concentration formulation. The value of this benefit to the consumer and ultimately for our shareholders cannot be underestimated and will improve the commercial value for our shareholders," added Dr. Verrico.

About Sirona Biochem Corp.

Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona's subsidiary lab, TFChem, specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.

Sirona's compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and continuing royalty payments.

We seek Safe Harbor.